Literature DB >> 7915094

Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.

S E Lee1, N H Chow, Y C Chi, T S Tzai, W H Yang, S N Lin.   

Abstract

The clinical significance of c-erb B-2 expression in urinary bladder cancer remains controversial. We performed an immunohistochemical study to examine the expression of c-erb B-2 in non-neoplastic urothelium (n = 12) and transitional cell carcinoma of the urinary bladder (n = 82). c-erb B-2 protein was localized in superficial and some intermediate cells of non-neoplastic urothelium. A total of 29 out of 82 (35%) tumors were positive for c-erb B-2 over-expression. There was no significant association of c-erbB-2 expression with tumor grade (p = 0.12), stage (p = 0.93), DNA ploidy status (p = 0.56) and the sex of patients (p = 0.5). Expression of epidermal growth factor receptor and Ki-67 index was available in 33 cases. Both parameters showed no apparent association with c-erbB-2 expression (p = 0.53 and 0.58 respectively). Factors correlated with poor patient survival by univariate analysis were tumor stage (p = 0.0001), tumor grade (p = 0.001), development of second recurrence (p = 0.002) and negative expression of c-erbB-2 (p = 0.017). Important indicators associated with first recurrence were tumor stage (p = 0.028), and c-erbB-2 expression with the risk of second recurrence (p = 0.031). Multivariate survival analysis revealed that tumor stage was among the most important prognostic factors (p = 0.029), followed by tumors without c-erbB-2 expression (p = 0.031) with a median follow-up at 46 months. The age of patients and c-erbB-2 expression were significantly associated with developing second recurrence (p = 0.031 and 0.046 respectively). The results indicate that expression of c-erbB-2 is independent of the stage and grade of bladder cancer. Although c-erbB-2 status can discriminate subpopulations with a high risk of recurrence, evaluation of its expression in paraffin-embedded tumors does not indicate poor prognosis for patients with urinary bladder cancer. To address this discrepancy a better understanding of the regulatory mechanism and physiological properties of c-erbB-2 protein in urothelium is required.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915094

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 2.  Epidermal growth factor receptor and bladder cancer.

Authors:  A J Colquhoun; J K Mellon
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

3.  Bladder cancer: can we move beyond chemotherapy?

Authors:  Arlene Siefker-Radtke
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

4.  Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.

Authors:  Gonzague de Pinieux; Delphine Colin; Anne Vincent-Salomon; Jérôme Couturier; Delphine Amsellem-Ouazana; Philippe Beuzeboc; Annick Vieillefond
Journal:  Virchows Arch       Date:  2004-03-17       Impact factor: 4.064

5.  Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder.

Authors:  Khaled El Gehani; Lamia Al-Kikhia; Fatma Emaetig; Kari Syrjänen; Omran Al-Fituri; Adam Elzagheid
Journal:  Libyan J Med       Date:  2012-03-08       Impact factor: 1.657

6.  Clinicopathological features of bladder cancer associated with chronic exposure to arsenic.

Authors:  N H Chow; Y L Guo; J S Lin; J H Su; T S Tzai; H R Guo; I J Su
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.